For research use only. Not for therapeutic Use.
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment[1].
IRAK4-IN-7 has anti-cancer and anti-inflammatory activities, it can be used for cancer and inflammatory diseases treatment[1].
| Catalog Number | I012999 |
| CAS Number | 1801343-74-7 |
| Synonyms | 6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide |
| Molecular Formula | C21H19N7O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H19N7O3/c22-18-5-4-13(11-23-18)15-2-1-3-16(26-15)20(29)25-14-10-17-19(24-12-14)27-21(31-17)28-6-8-30-9-7-28/h1-5,10-12H,6-9H2,(H2,22,23)(H,25,29) |
| InChIKey | RWIMETUXCNDSLE-UHFFFAOYSA-N |
| SMILES | C1COCCN1C2=NC3=C(O2)C=C(C=N3)NC(=O)C4=CC=CC(=N4)C5=CN=C(C=C5)N |
| Reference | [1]. Venkateshwar Rao GUMMADI, et al. Bicyclic heterocyclyl derivatives as irak4 inhibitors. WO2015104688A1. |
